Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 18/20 | 1.00 |
| ▸ | NR1H2 | P55055 | 9/20 | 0.61 |
| ▸ | RXRA | P19793 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | VHL | P40337 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4086616 | 0.93 | NR1H3 (0.86) | NR1H3NR1H2RXRAALDH1A1MEN1 | |
| SCHEMBL6513579 | 0.90 | NR1H3 (0.81) | NR1H3NR1H2RXRAALDH1A1MEN1 | |
| SCHEMBL4095145 | 0.89 | NR1H3 (0.80) | NR1H3NR1H2RXRAALDH1A1MEN1 | |
| SCHEMBL4092532 | 0.87 | NR1H3 (0.77) | NR1H3NR1H2RXRAALDH1A1MEN1 | |
| SCHEMBL6515333 | 0.84 | NR1H3 (0.83) | NR1H3NR1H2RXRAALDH1A1MEN1 | |
| SCHEMBL4097347 | 0.84 | NR1H3 (0.72) | NR1H3NR1H2RXRAALDH1A1MEN1 | |
| SCHEMBL6510880 | 0.83 | NR1H3 (0.87) | NR1H3NR1H2RXRAALDH1A1MEN1 | |
| SCHEMBL4950275 | 0.83 | NR1H3 (1.00) | NR1H3NR1H2RXRAALDH1A1MEN1 | |
| SCHEMBL30730688 | 0.83 | NR1H3 (1.00) | NR1H3NR1H2RXRAALDH1A1MEN1 | |
| SCHEMBL6519559 | 0.83 | NR1H3 (0.76) | NR1H3NR1H2RXRAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050282908-A1 | Substituted aminopropoxyaryl derivatives useful as agonists for LXR | SMITHKLINE BEECHAM CORPORATION | 2005-12-22 | — | — | US | claimed |
| EP-1318976-B1 | SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR | GLAXO GROUP LTD (GB) | 2004-11-24 | — | — | EP | claimed |
| US-20040072868-A1 | Substitued aminopropoxyaryl derivatives useful as agonists for lxr | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | claimed |
| JP-2004509161-A | — | — | 2004-03-25 | — | — | JP | claimed |
| EP-1318976-A2 | SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR | GLAXO GROUP LIMITED (GB) | 2003-06-18 | — | — | EP | claimed |
| WO-2002024632-A2 | SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR | GLAXO GROUP LIMITED (GB) | 2002-03-28 | — | — | WO | claimed |
| US-20050282908-A1 | Substituted aminopropoxyaryl derivatives useful as agonists for LXR | SMITHKLINE BEECHAM CORPORATION | 2005-12-22 | — | — | US | disclosed |
| EP-1318976-B1 | SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR | GLAXO GROUP LTD (GB) | 2004-11-24 | — | — | EP | disclosed |
| US-20040072868-A1 | Substitued aminopropoxyaryl derivatives useful as agonists for lxr | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | disclosed |
| EP-1318976-A2 | SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR | GLAXO GROUP LIMITED (GB) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024632-A2 | SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR | GLAXO GROUP LIMITED (GB) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282908-A1 | Substituted aminopropoxyaryl derivatives useful as agonists for LXR | NR1H3, NR1H2, NR1H4 | NR1H3 1/4885NR1H2 2/4885RXRA 28/4885 |
| US-20040072868-A1 | Substitued aminopropoxyaryl derivatives useful as agonists for lxr | NR1H2, NR1H3, NR1H4 | NR1H3 2/4885NR1H2 1/4885RXRA 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.